Your browser doesn't support javascript.
loading
Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.
Itchins, M; Chia, P L; Hayes, S A; Howell, V M; Gill, A J; Cooper, W A; John, T; Mitchell, P; Millward, M; Clarke, S J; Solomon, B; Pavlakis, N.
Afiliação
  • Itchins M; Bill Walsh Translational Research Laboratory, Kolling Institute Medical Institute of Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Chia PL; Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
  • Hayes SA; Northern Cancer Institute, St Leonards, New South Wales, Australia.
  • Howell VM; Medical Oncology Unit, Olivia Newton John Cancer and Wellness Centre, Austin Health, Melbourne.
  • Gill AJ; Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
  • Cooper WA; Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
  • John T; Bill Walsh Translational Research Laboratory, Kolling Institute Medical Institute of Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Mitchell P; Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
  • Millward M; Bill Walsh Translational Research Laboratory, Kolling Institute Medical Institute of Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Clarke SJ; Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
  • Solomon B; Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
  • Pavlakis N; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Asia Pac J Clin Oncol ; 13 Suppl 3: 3-13, 2017 Aug.
Article em En | MEDLINE | ID: mdl-28795492
ABSTRACT
Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Neoplasias Pulmonares / Antineoplásicos Limite: Humans País/Região como assunto: Oceania Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Neoplasias Pulmonares / Antineoplásicos Limite: Humans País/Região como assunto: Oceania Idioma: En Ano de publicação: 2017 Tipo de documento: Article